Core Viewpoint - The Chinese pharmaceutical industry is experiencing a significant transformation driven by technological breakthroughs and demographic changes, leading to a shift from a reliance on license-in to license-out strategies, positioning Chinese companies as key players in the global market [2][4][11]. Group 1: Industry Trends - The Hong Kong pharmaceutical sector is witnessing a surge, with ETFs tracking the Hang Seng Biotechnology Index showing strong performance, indicating a structural change in the industry [1][3]. - Innovation drugs are becoming a major investment theme for 2025, with significant year-to-date gains in related indices, highlighting the leading role of companies like WuXi Biologics and BeiGene [4][5]. - The Chinese pharmaceutical industry now ranks second globally, with approximately 30% of innovative drugs under development worldwide, and a notable increase in the approval rate of new drugs [8][9]. Group 2: Technological Advancements - The advent of CRISPR gene editing and AI technologies is revolutionizing drug development, significantly reducing research and development cycles and enhancing the capabilities of Chinese pharmaceutical companies [2][7]. - The emergence of platform technologies such as ADCs, bispecific antibodies, and cell therapies is opening new avenues for drug development, contributing to the increased competitiveness of domestic biotech products [7]. Group 3: Market Dynamics - The market is currently experiencing a revaluation of innovative drug companies, with many leading firms turning profitable and their valuations being reassessed positively [7][11]. - The increase in license-out transactions indicates a shift in the global innovation chain, with Chinese companies now accounting for over 51% of the total transaction value in the BD market [11]. Group 4: Policy and Financial Environment - Supportive policies, including stable medical insurance negotiations and expedited drug approval processes, are fostering an environment conducive to innovation [8]. - The easing of monetary policy, including interest rate cuts by the Federal Reserve, is providing a favorable financing environment for biotech companies, further enhancing their growth prospects [8]. Group 5: Investment Opportunities - The Hang Seng Medical ETF and the Hong Kong Stock Connect Medical ETF are emerging as attractive investment vehicles, providing exposure to core assets in the Hong Kong pharmaceutical sector [3][15]. - The recent restructuring of the Hang Seng Biotechnology Index has improved its focus on leading companies in the biotech field, enhancing its investment appeal [14][15].

Core Viewpoint - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index (000698) has shown strong performance, with a notable increase in constituent stocks, driven by favorable policies and high industry activity in the semiconductor sector [1] Group 1: Index Performance - As of September 24, 2025, the Sci-Tech Innovation Board 100 Index rose by 2.79%, with significant gains in stocks such as Micro導納米 (688147) up 16.40%, and Anji Technology (688019) up 14.06% [1] - The Sci-Tech 100 ETF Fund (588220) increased by 2.83%, with the latest price at 1.38 yuan and a total scale of 6.895 billion yuan, ranking first among similar funds [1] Group 2: Industry Insights - The semiconductor industry chain has collectively surged, with institutions noting a resonance between ongoing policy support, high industry prosperity (recovery of the semiconductor cycle, overseas expansion of innovative drugs), and capital inflow [1] - In the medium to long term, attention should be paid to the third-quarter earnings reports, particularly focusing on the performance of semiconductor equipment and the R&D conversion efficiency of innovative pharmaceutical companies [1] Group 3: Index Composition - The top ten weighted stocks in the Sci-Tech Innovation Board 100 Index as of August 29, 2025, include Dongxin Co. (688110), Huahong Semiconductor (688347), and BeiGene (688235), collectively accounting for 23.82% of the index [2]

Core Insights - The pharmaceutical industry is experiencing a resurgence driven by innovation, favorable policies, and an aging population, positioning it as a key investment opportunity [2][5][6] Historical Market Review - The pharmaceutical sector has undergone multiple market cycles over the past fifteen years, with significant performance variations influenced by unique driving factors [2] - From 2009 to 2010, the industry saw a substantial rebound due to the "four trillion" policy, resulting in a 148.46% increase in the CSI Pharmaceutical Index, outperforming the Shanghai Composite Index's 54.22% rise [2][3] - Between 2013 and 2015, the sector faced stricter regulations, leading to a mixed performance where it did not outperform the ChiNext Index, although new themes like smart healthcare gained traction [3] - The period from 2019 to 2021 was marked by a strong performance driven by the pandemic, with the CXO Index surging 277.13% [3] - In 2024, the pharmaceutical sector faced challenges, with the CSI Pharmaceutical Index declining 14.53%, underperforming the CSI 300 Index [4] Current Investment Value Analysis - The current valuation of the pharmaceutical sector is considered reasonable after prior adjustments, with some indices showing attractive investment metrics [5] - Leading pharmaceutical companies are expected to maintain stable growth due to the commercialization of innovative drugs and steady performance in traditional drug segments [5] - The aging population is projected to drive increased healthcare demand, with 22.0% of the population aged 60 and above by the end of 2024 [5] - There has been a notable inflow of funds into the medical device sector, indicating growing market confidence in certain pharmaceutical sub-sectors [5][6] Policy Environment - The policy focus is shifting from cost control to innovation-driven growth, with reforms in the medical insurance payment system and expedited drug approval processes [6] - The National Medical Insurance Administration plans to expand the medical insurance drug list, which will benefit the industry's innovation and profitability [6] Innovation in Pharmaceuticals - Innovative drugs are becoming the focal point of the Chinese pharmaceutical industry, with significant advancements in areas like oncology and antibody-drug conjugates [7] - The total value of license-out deals for Chinese innovative drugs surpassed $60 billion in the first half of 2025, indicating a strong international presence [7] Investment Participation Strategies - Investors are encouraged to adopt a systematic investment approach to mitigate short-term volatility, as the pharmaceutical sector is characterized by long-term growth potential [9] - Focus on sectors with strong policy support and international expansion opportunities, such as innovative drugs and medical devices, is recommended [9]

Core Insights - The significant stock price increases of Kangfang Biopharma and Pop Mart, exceeding 150% and 450% respectively, reflect the accurate predictions of the "2024 Phoenix Star Listed Company Awards" regarding high-quality companies [1][3][14] Company Performance - Kangfang Biopharma achieved a revenue of 1.412 billion yuan in the first half of 2025, marking a year-on-year growth of 33.7%, driven by the commercialization of core products [3][5] - Pop Mart reported a revenue of 13.88 billion yuan during the same period, with a remarkable year-on-year growth of 204.4%, showcasing its strong monetization capabilities in cultural IP operations [5][9] Strategic Initiatives - Both companies are actively pursuing globalization strategies to tap into overseas market potential, which is crucial for their scale expansion [5][6] - Kangfang Biopharma's key products, such as Cardunili and Yivosi, are being commercialized globally, with significant licensing agreements and clinical trials underway in the U.S. [5][9] - Pop Mart is adapting its international strategy by signing local artists and creating products tailored to regional consumer preferences, enhancing its global appeal [6][9] Industry Trends - The innovative pharmaceutical sector, where Kangfang Biopharma operates, is experiencing structural changes, including improved healthcare systems and accelerated drug approvals, contributing to the growth of Chinese innovative drug companies [9][10] - Pop Mart is capitalizing on the rise of the IP economy, driven by the increasing demand for emotional value consumption among Generation Z and the global popularity of "Guzi" culture [9][10] Evaluation Criteria - The "Phoenix Star" awards focus on companies' core competitiveness and long-term industry impact rather than short-term financial metrics, highlighting the potential for sustained growth [10][12] - The evaluation process includes data analysis, expert reviews, and public voting, ensuring a comprehensive assessment of companies' long-term value [10][12]

华鑫证券认为，中国创新药出海是创新成果持续涌现和创新效率驱动的结果，全球新药研发向中国转 移，是不可逆转的产业趋势，虽然在短期内或出现波动，但全年增长的趋势不变。 在创新药出海热潮的强力驱动下，国内创新药板块迎来显著复苏。从中报数据来看，较多创新药企成功 实现扭亏为盈，业绩基本面的改善直接点燃了市场对创新药板块的投资热情，板块估值修复行情延续。 港股医药板块午后拉升，恒生医药ETF（159892）涨超2%，药明合联领涨，诺诚健华、药明生物、药 明康德、晶泰控股等跟涨。 2025年以来，中国创新药领域License-out交易频发。据医药魔方数据，2025年上半年，中国License-out 交易共计72笔，交易总金额较2024年全年高出16%，其中单笔金额超过10亿美元的交易达16笔，重磅交 易的落地提升了市场对创新药出海的信心。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 21, 2025 [1] Core Insights - The trend of Chinese innovative drugs going global is a significant industry trend, with a notable increase in License-out transactions in the first half of 2025, surpassing the total number for 2024 by over half and increasing transaction amounts by 16% [2] - The report highlights the importance of structural opportunities within the industry, emphasizing the need to select high-quality companies amidst the competitive landscape [2] - The report notes that while the trend of innovative drugs going abroad continues, concerns have arisen due to fewer major transactions and proposed U.S. regulations affecting Chinese drug licensing [2] - The report identifies significant breakthroughs in small nucleic acid drugs, particularly in chronic disease areas such as hypertension, with notable partnerships and potential milestone payments [3] - The report discusses promising clinical data from Chinese ADCs presented at the World Lung Cancer Conference, showcasing competitive advantages in efficacy and safety [4] - The report mentions the advancements in GLP-1 analogs for weight loss, with ongoing developments from both multinational corporations and domestic companies [5] - The CXO sector is expected to gradually recover, driven by an increase in orders and favorable policy changes [6] - The report outlines the completion of expert reviews for the 2025 medical insurance negotiation and commercial insurance innovative drug directories, indicating potential impacts on participating companies [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has underperformed compared to the CSI 300 index, with a recent weekly decline of 2.07% [22] - Over the past month, the industry has lagged behind the CSI 300 index by 7.79 percentage points [23] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 39.77, above the five-year historical average of 31.50 [48] 3. Recent Research Achievements - The report includes various recent research outputs, highlighting the ongoing focus on innovative drug development and market opportunities [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Medical Insurance Administration regarding drug directory adjustments and the implications for the industry [52][54]

Core Insights - 60% of biotech respondents believe the innovative drug primary market has emerged from its lowest point, but conditions remain suboptimal; 33% see no significant change, indicating a continued capital winter [1][5][10] - The survey highlights that 67% of biotech respondents face challenges in financing due to high professional barriers and a lack of understanding from investors regarding innovative drug logic [3][10] - The investment environment is perceived to have improved slightly, yet investors remain cautious, with a belief that the enthusiasm in the secondary market has yet to translate to the primary market [4][26] Group 1: Financing Challenges - 67% of biotech respondents cite high professional barriers as a primary challenge in securing financing, while 52% point to stringent financing conditions such as performance guarantees [3][10] - In the first half of 2025, there were 188 financing events in the domestic innovative drug primary market, a 7.4% year-on-year decline, with total financing amounting to approximately $1.58 billion, down 24.5% from the previous year [5][10] - Many biotech founders report difficulties in securing funding, with one entrepreneur stating that it typically requires discussions with at least 100 institutions to secure investment [5][10] Group 2: Market Dynamics - The innovative drug sector has seen a resurgence in stock prices, with over 60 companies experiencing a doubling of their stock prices, driven by numerous business development (BD) transactions [5][10] - Investors are increasingly focused on the ability of drugs to enter international markets, which often indicates imminent returns [16][26] - The current investment logic has shifted towards a focus on commercialization capabilities, with investors now requiring clear evidence of potential milestones and commercial viability [12][14] Group 3: Exit Strategies - 74% of biotech respondents believe that the lack of smooth exit channels is a major factor affecting the current investment climate in the innovative drug primary market [19][20] - Many investors express concerns about the difficulty of exiting previous investments, with 8 out of 10 investors indicating that exit channels remain constrained [19][20] - The trend of BD transactions is emerging as a potential exit strategy, although it is still not widely adopted, with only a small percentage of investment agreements including BD clauses [20][22] Group 4: Future Outlook - There is a concern that the current wave of BD transactions may lead to a gap in new investments, as the focus on established projects may overshadow the need for funding new innovations [25] - Investors believe that for the primary market to recover, there needs to be a stable policy environment and visible success in the secondary market that can encourage further investment [26] - The industry is facing a potential decline in entrepreneurial activity, with a shift in investment focus from companies to specific drug pipelines, raising concerns about long-term industry vitality [26]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Market Overview - In the recent trading period from September 12 to September 18, major indices showed mixed performance, with the Shanghai Composite Index declining by 1.13% and the ChiNext Index increasing by 1.38% [2] - The trading volume increased, with a total of 12.65 trillion yuan traded, averaging 2.53 trillion yuan per day, which is an increase of 278.79 billion yuan compared to the previous five trading days [2] Economic Data - From January to August, fixed asset investment grew by 0.5% year-on-year, reflecting a marginal decline of 1.1 percentage points [3] - The total retail sales of consumer goods from January to August increased by 4.6% year-on-year, which is a decrease of 0.2 percentage points compared to July [3] Policy Developments - Recently, the Ministry of Commerce and eight other departments issued measures to expand service consumption, proposing 19 measures focused on promoting consumption and expanding domestic demand [3] - The policy measures indicate a proactive approach to stimulate service consumption in light of the need to boost consumer demand [3] International Developments - On September 18, the Federal Reserve lowered the federal funds rate by 25 basis points, bringing the target range to 4.00% to 4.25%, aligning with market expectations [3] - The Fed's forecast for the policy rate in 2025 has been adjusted down to 3.6%, suggesting a potential for an additional 50 basis points of rate cuts within the year, indicating a trend towards further easing of overseas liquidity [3] Investment Strategy - The A-share market is exhibiting strong structural characteristics, with a focus on stabilizing the overall market while the technology-driven sectors are showing active performance [3] - The continuation of liquidity inflow will be crucial for maintaining the current structural market trends [3] Industry Focus - Investment opportunities are identified in the TMT sector due to the promotion of domestic alternatives in computing power and the upcoming peak season for smart terminal releases [4] - Other sectors with potential investment opportunities include pharmaceuticals, power equipment, non-ferrous metals, and machinery, driven by factors such as innovative drug exports, high demand for energy storage, and the anticipated mass production of robots [4]

Core Insights - The conference highlighted the growing global competitiveness of Chinese innovative drugs, particularly in areas like ADC and bispecific antibodies, while emphasizing the need for improvement in original innovation capabilities [1][5][6] - There is a consensus among industry leaders that "going global" is essential for the future of Chinese innovative drugs, with calls for more supportive policies to facilitate this process [1][7][9] Group 1: Current State of Chinese Innovative Drugs - Chinese innovative drugs have reached a global competitiveness level from "1 to 10," especially in engineering fields, but still need to enhance original innovation from "0 to 1" [1] - The quality of projects is crucial for international expansion, as highlighted by industry leaders who stress that strong data and comprehensive packages are essential for success [2][3] - The past decade has seen significant development in the Chinese innovative drug ecosystem, with a complete industrial chain now in place, particularly in cities like Shanghai [4] Group 2: Challenges and Opportunities - The domestic market's limitations are pushing companies to explore international markets, with a focus on countries involved in the Belt and Road Initiative [7] - There is a need for policy reforms regarding listing standards to support innovative drug companies that face long development cycles and high R&D costs [7][9] - The current pricing of innovative drugs in international markets is still influenced by domestic prices, which poses challenges for global competitiveness [9] Group 3: Future Directions and Innovations - The industry is witnessing a surge in various therapeutic areas, including small molecules, antibodies, peptides, RNA, and gene therapies, indicating a diverse landscape of innovation [10] - The potential for small nucleic acids and other novel therapies is recognized as a significant opportunity for Chinese companies to lead in the global market [10] - Industry leaders express confidence in the future of Chinese innovative drugs, anticipating that with time, more companies will emerge as global players [11]